M G Achen

Summary

Affiliation: Ludwig Institute for Cancer Research
Country: Australia

Publications

  1. pmc Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer
    Jane E Girling
    Centre for Women s Health Research, Monash Institute of Medical Research and Monash University Department of Obstetrics and Gynaecology, Monash Medical Centre, 246 Clayton Rd, Clayton, VIC 3168, Australia
    Reprod Biol Endocrinol 8:84. 2010
  2. doi Molecular control of lymphatic metastasis
    Marc G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria 3050, Melbourne, Australia
    Ann N Y Acad Sci 1131:225-34. 2008
  3. ncbi Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis
    M G Achen
    Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia
    J Pathol 193:147-54. 2001
  4. ncbi Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3
    M G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Eur J Biochem 267:2505-15. 2000
  5. ncbi Tumor lymphangiogenesis and metastatic spread-new players begin to emerge
    Marc G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria 3050, Australia
    Int J Cancer 119:1755-60. 2006
  6. pmc Targeting lymphangiogenesis to prevent tumour metastasis
    M G Achen
    Ludwig Institute for Cancer Research, Post Office Box 2008 Royal Melbourne Hospital, Victoria 3050, Australia
    Br J Cancer 94:1355-60. 2006
  7. pmc The vascular endothelial growth factor family; proteins which guide the development of the vasculature
    M G Achen
    Angiogenesis Laboratory, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Int J Exp Pathol 79:255-65. 1998
  8. ncbi Focus on lymphangiogenesis in tumor metastasis
    Marc G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Cancer Cell 7:121-7. 2005
  9. pmc Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
    M G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Proc Natl Acad Sci U S A 95:548-53. 1998
  10. pmc Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D
    Bradley K McColl
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia
    J Exp Med 198:863-8. 2003

Collaborators

Detail Information

Publications49

  1. pmc Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer
    Jane E Girling
    Centre for Women s Health Research, Monash Institute of Medical Research and Monash University Department of Obstetrics and Gynaecology, Monash Medical Centre, 246 Clayton Rd, Clayton, VIC 3168, Australia
    Reprod Biol Endocrinol 8:84. 2010
    ..We hypothesised that VEGF-D over-expression would stimulate growth of new lymphatic vessels into the endometrium, thereby contributing to cancer progression...
  2. doi Molecular control of lymphatic metastasis
    Marc G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria 3050, Melbourne, Australia
    Ann N Y Acad Sci 1131:225-34. 2008
    ..This article provides an overview of the molecular mechanisms that control lymphatic metastasis and discusses potential therapeutic approaches for inhibiting this process in human cancer...
  3. ncbi Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis
    M G Achen
    Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia
    J Pathol 193:147-54. 2001
    ....
  4. ncbi Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3
    M G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Eur J Biochem 267:2505-15. 2000
    ..The anti-(VEGF-D) mAbs raised to the bioactive region of this growth factor will be powerful tools for analysis of the biological functions of VEGF-D...
  5. ncbi Tumor lymphangiogenesis and metastatic spread-new players begin to emerge
    Marc G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria 3050, Australia
    Int J Cancer 119:1755-60. 2006
    ..Molecular approaches for inhibiting lymphangiogenic signaling in cancer, designed to restrict tumor metastasis, are also examined...
  6. pmc Targeting lymphangiogenesis to prevent tumour metastasis
    M G Achen
    Ludwig Institute for Cancer Research, Post Office Box 2008 Royal Melbourne Hospital, Victoria 3050, Australia
    Br J Cancer 94:1355-60. 2006
    ..In this review, we discuss the evidence supporting a role for this signalling system in the spread of cancer and potential approaches for blocking this system to prevent tumour metastasis...
  7. pmc The vascular endothelial growth factor family; proteins which guide the development of the vasculature
    M G Achen
    Angiogenesis Laboratory, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Int J Exp Pathol 79:255-65. 1998
    ..The availability of purified VEGF family members and of inhibitors of these growth factors may provide a means to modulate blood vessel growth for the treatment of cancer, retinopathies and diseases of ischemia...
  8. ncbi Focus on lymphangiogenesis in tumor metastasis
    Marc G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Cancer Cell 7:121-7. 2005
  9. pmc Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
    M G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Proc Natl Acad Sci U S A 95:548-53. 1998
    ..In addition, VEGF-D is a mitogen for endothelial cells. The structural and functional similarities between VEGF-D and VEGF-C define a subfamily of the VEGFs...
  10. pmc Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D
    Bradley K McColl
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia
    J Exp Med 198:863-8. 2003
    ..Identification of an enzyme that activates the lymphangiogenic growth factors will facilitate development of inhibitors of metastasis...
  11. ncbi The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer
    Marc G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Growth Factors 20:99-107. 2002
    ..These data indicate that VEGF-D promotes tumor angiogenesis, lymphangiogenesis and metastatic spread by a paracrine mechanism...
  12. ncbi The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man
    M E Baldwin
    Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Victoria 3050 Australia
    J Biol Chem 276:19166-71. 2001
    ..This suggests that VEGF-D and VEGFR-3 may play a role in establishing vessels of the skin by a paracrine mechanism. Our study of receptor specificity suggests that VEGF-D may have different biological functions in mouse and man...
  13. ncbi A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability
    S A Stacker
    Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Victoria 3050 Australia
    J Biol Chem 274:34884-92. 1999
    ..These data suggest different mechanisms for VEGF-mediated mitogenesis and vascular permeability and raise the possibility of an alternative receptor mediating vascular permeability...
  14. ncbi Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers
    S A Stacker
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
    J Biol Chem 274:32127-36. 1999
    ..In situ hybridization demonstrated that embryonic lung is a major site of expression of the VEGF-D gene. Processed forms of VEGF-D were detected in embryonic lung indicating that VEGF-D is proteolytically processed in vivo...
  15. ncbi VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
    S A Stacker
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Nat Med 7:186-91. 2001
    ..This study demonstrates that lymphatics can be established in solid tumors and implicates VEGF family members in determining the route of metastatic spread...
  16. ncbi Placenta growth factor and vascular endothelial growth factor are co-expressed during early embryonic development
    M G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Growth Factors 15:69-80. 1997
    ..The secretion of PIGF and VEGF by trophoblastic giant cells is likely to be the signal which initiates and co-ordinates vascularization in the deciduum and placenta during early embryogenesis...
  17. ncbi Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis
    M E Baldwin
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Post Office Box 2008, Victoria 3050, Australia
    J Biol Chem 276:44307-14. 2001
    ..The isoforms are differently glycosylated when expressed in vitro. This study demonstrates that RNA splicing, protein glycosylation, and proteolysis are mechanisms for generating structural diversity of mouse VEGF-D...
  18. ncbi Molecular targeting of lymphatics for therapy
    S A Stacker
    Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia
    Curr Pharm Des 10:65-74. 2004
    ..Modulating these pathways and other molecules with specificity to the lymphatic system could offer alternative treatments for a number of important clinical conditions...
  19. ncbi Current strategies for modulating lymphangiogenesis signalling pathways in human disease
    S A Stacker
    Angiogenesis Laboratory, Ludwig Institute for Cancer Research, PO Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia
    Curr Med Chem 13:783-92. 2006
    ..Modulating these pathways and other molecules with specificity to the lymphatic endothelium could offer alternative treatments for a number of important clinical conditions...
  20. ncbi Molecular control of lymphangiogenesis
    Megan E Baldwin
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Bioessays 24:1030-40. 2002
    ..The capacity to induce lymphangiogenesis by manipulation of the VEGF-C/VEGF-D/VEGFR-3 signaling pathway offers new opportunities to understand the function of the lymphatic system and to develop novel treatments for lymphatic disorders...
  21. ncbi Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2
    Bradley K McColl
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria 3050, Australia
    FASEB J 21:1088-98. 2007
    ..The finding that PCs promote activation of VEGF-D and other proteins with roles in cancer such as matrix metalloproteinases, emphasizes the importance of these enzymes as potential regulators of tumor progression and metastasis...
  22. ncbi Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer
    Yiping Zeng
    Bernard O Brien Institute of Microsurgery, Melbourne, Australia
    Clin Cancer Res 10:5137-44. 2004
    ..The purpose of this study was to determine the expression pattern of the VEGF-C/VEGF-D/VEGF receptor-3 axis in prostate cancer and its relationship with lymph node metastasis...
  23. ncbi Sampling the genomic pool of protein tyrosine kinase genes using the polymerase chain reaction with genomic DNA
    A C Oates
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Victoria, Australia
    Biochem Biophys Res Commun 249:660-7. 1998
    ..Furthermore, as a tool to hasten the discovery of members of gene families that are of particular interest, this method offers an opportunity to sample the genome for new members irrespective of their expression pattern...
  24. doi From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy
    Steven A Stacker
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Lymphat Res Biol 6:165-72. 2008
    ..History may show that anti-angiogenesis provided the vantage point from which anti-lymphangiogenesis was seen as a viable concept for targeting tumors and other pathological conditions...
  25. ncbi Lymphangiogenesis and cancer metastasis
    Steven A Stacker
    Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia
    Nat Rev Cancer 2:573-83. 2002
    ..This article reviews recent experimental and clinico-pathological data indicating that growth factors that stimulate lymphangiogenesis in tumours are associated with an enhanced metastatic process...
  26. ncbi The role of tumor lymphangiogenesis in metastatic spread
    Steven A Stacker
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria 3050, Australia
    FASEB J 16:922-34. 2002
    ..These studies demonstrate that tumor lymphangiogenesis is a major component of the metastatic process and implicate members of the VEGF family of growth factors as key mediators of lymphangiogenesis in both normal biology and tumors...
  27. ncbi Lymphangiogenic growth factors as markers of tumor metastasis
    Steven A Stacker
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    APMIS 112:539-49. 2004
    ..The question of whether VEGF signaling pathways can now serve as therapeutic targets alone, or in combination with other forms of anti-cancer agents, needs to be addressed...
  28. ncbi Molecular regulation of the VEGF family -- inducers of angiogenesis and lymphangiogenesis
    Bradley K McColl
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    APMIS 112:463-80. 2004
    ..An understanding of these mechanisms offers broader opportunities to manipulate expression and activity of the VEGFs for treatment of disease...
  29. pmc Vascular endothelial growth factor D is dispensable for development of the lymphatic system
    Megan E Baldwin
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, PO Box 2008, Parkville, Victoria 3050, Australia
    Mol Cell Biol 25:2441-9. 2005
    ....
  30. ncbi A system for quantifying the patterning of the lymphatic vasculature
    Ramin Shayan
    Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Growth Factors 25:417-25. 2007
    ..This efficient, reproducible technique is validated by analysing healthy and pathological tissues...
  31. ncbi Lymphatic vessels in cancer metastasis: bridging the gaps
    Ramin Shayan
    Angiogenesis Laboratory, Ludwig Institute for Cancer Research, PO Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia
    Carcinogenesis 27:1729-38. 2006
    ..Current ideas about the roles of lymphangiogenic growth factors, their signalling pathways in lymphatic metastasis and therapeutic opportunities to restrict this spread will also be explored...
  32. pmc Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer
    P Balanathan
    Centre for Urological Research, Monash Institute of Medical Research, Monash University, Melbourne, Victoria 3168, Australia
    Br J Cancer 100:1784-93. 2009
    ..Our results also suggest that INH alpha expression in the primary prostate tumour can be used as a predictive factor for prognosis of PCa...
  33. ncbi Molecular pathways for lymphangiogenesis and their role in human disease
    Steven A Stacker
    Angiogenesis Laboratory, Ludwig Institute for Cancer Research, PO Box 2008, Royal Melbourne Hospital, 3050, Victoria, Australia
    Novartis Found Symp 281:38-43; discussion 44-53, 208-9. 2007
    ..Knowledge of these molecular pathways allows for the generation of modulators of these pathways which could form the basis of novel therapeutic approaches...
  34. ncbi Mechanisms of lymphangiogenesis: targets for blocking the metastatic spread of cancer
    Bradley K McColl
    Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia
    Curr Cancer Drug Targets 5:561-71. 2005
    ..Strategies to block the actions of these proteins in cancer are also explored...
  35. ncbi Vascular remodeling in cancer
    R H Farnsworth
    Protein Interaction and Cancer Research Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
    Oncogene 33:3496-505. 2014
    ..This review, which primarily focuses on the blood vasculature, explores current knowledge of how tumor vessels can be remodeled, and the cellular and molecular events responsible for this process. ..
  36. ncbi Lymphatic endothelium: an important interactive surface for malignant cells
    Rae H Farnsworth
    Ludwig Institute for Cancer Research, P O Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia
    Pulm Pharmacol Ther 19:51-60. 2006
    ..This review provides a synopsis of the recent data pertaining to the purification and culture of lymphatic endothelial cells, and the interaction of tumour cells with lymphatic endothelium...
  37. ncbi The distribution of cerebral expression of the transferrin gene is species specific
    G F Tu
    Russell Grimwade School of Biochemistry, University of Melbourne, Parkville, Victoria, Australia
    J Biol Chem 266:6201-8. 1991
    ..In conclusion, a striking species specificity was observed for the pattern of cerebral expression of the transferrin gene...
  38. ncbi Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer
    Zofia Von Marschall
    Department of Hepatology, Gastroenterology, Endocrinology and Metabolism, Charite University Medicine Berlin, CVK, D 13353 Berlin, Germany
    Int J Oncol 27:669-79. 2005
    ..Our results suggest that VEGF-D plays a pivotal role in stimulating lymphangiogenesis and lymphatic metastasis in human ductal pancreatic cancer, and therefore represents a novel therapeutic target for this devastating disease...
  39. ncbi Regenerating lizard tails: a new model for investigating lymphangiogenesis
    Christopher B Daniels
    Department of Environmental Biology, University of Adelaide, Adelaide SA 5005, Australia
    FASEB J 17:479-81. 2003
    ..Regenerating lizard tails are potentially useful models for studying the molecular basis of lymphangiogenesis with a view to developing possible treatments for human lymphoedema...
  40. ncbi Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens
    Lyn M Wise
    Virus Research Unit, Department of Microbiology, University of Otago, P O Box 56, Dunedin, New Zealand
    J Biol Chem 278:38004-14. 2003
    ..We propose that the extensive sequence divergence seen in the viral VEGFs was generated primarily by selection against VEGFR-1 binding...
  41. ncbi Vascular endothelial growth factor-D expression in human atherosclerotic lesions
    Juha Rutanen
    Department of Molecular Medicine, AI Virtanen Institute, University of Kuopio, PO Box 1627, FIN 70211 Kuopio, Finland
    Cardiovasc Res 59:971-9. 2003
    ..We studied the expression of VEGF-D and its receptors (VEGFR-2 and VEGFR-3) in normal and atherosclerotic human arteries, and compared that to the expression pattern of VEGF-A...
  42. ncbi Angiogenic responses of vascular endothelial growth factors in periadventitial tissue
    Shalini Bhardwaj
    Department of Biotechnology and Molecular Medicine, A I Virtanen Institute for Molecular Sciences, University of Kuopio, 70211 Kuopio, Finland
    Hum Gene Ther 14:1451-62. 2003
    ..It is concluded that VEGF-A, VEGF-D, and VEGF-D(deltaNdeltaC) are the best candidates for therapeutic angiogenesis when delivered around large arteries...
  43. pmc Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos
    Paula Haiko
    Molecular Cancer Biology Laboratory, Haartman Institute, Biomedicum Helsinki and Helsinki University Central Hospital, P O B 63 Haartmaninkatu 8, University of Helsinki, 00014 Helsinki, Finland
    Mol Cell Biol 28:4843-50. 2008
    ..Our results suggest VEGF-C- and VEGF-D-independent functions for VEGFR-3 in the early embryo...
  44. ncbi VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses
    Tuomas T Rissanen
    Department of Biotechnology and Molecular Medicine, A I Virtanen Institute, University of Kuopio, PO Box 1627, FIN 70211 Kuopio, Finland
    Circ Res 92:1098-106. 2003
    ..This study compares, for the first time, angiogenesis and lymphangiogenesis induced by gene transfer of different human VEGFs, and shows that VEGF-D is the most potent member when delivered via an adenoviral vector into skeletal muscle...
  45. pmc Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis
    Lucie Kopfstein
    Institute of Biochemistry and Genetics, Department of Clinical Biological Sciences, University of Basel, Center of Biomedicine, Mattenstrasse 28, CH 4058 Basel, Switzerland
    Am J Pathol 170:1348-61. 2007
    ....
  46. pmc Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation
    Peter Baluk
    Cardiovascular Research Institute, Comprehensive Cancer Center, and Department of Anatomy, UCSF, San Francisco, California 94143, USA
    J Clin Invest 115:247-57. 2005
    ..Correction of defective lymphangiogenesis may benefit the treatment of asthma and other inflammatory airway diseases...
  47. pmc Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation
    Terhi Karpanen
    Molecular Cancer Biology Laboratory, Biomedicum Helsinki, P O B 63 Haartmaninkatu 8, FI 00014 University of Helsinki, Finland
    Am J Pathol 169:708-18. 2006
    ..These results indicate considerable plasticity of lymphatic vessels during the early postnatal period but not thereafter, suggesting that anti-lymphangiogenic therapy can be safely applied in adults...
  48. ncbi Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo
    Tatiana V Byzova
    Department of Molecular Cardiology and Cardiology, The Cleveland Clinic Foundation, OH 44195, USA
    Blood 99:4434-42. 2002
    ....
  49. ncbi Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart
    Juha Rutanen
    Department of Molecular Medicine, A I Virtanen Institute, Kuopio University, Finland
    Circulation 109:1029-35. 2004
    ..Furthermore, the histological nature of angiogenesis and potential side effects caused by different vascular endothelial growth factors (VEGFs) in myocardium have not been documented...